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Enzymes are an essential component of most biotechnolog-
ical and biomedical processes[1] but their scope of application
is hampered by a limited stability under often desired harsh
conditions (e.g., elevated temperature or presence of dena-
turants). Consequently, the stabilization of protein structures
is essential when developing suitable enzymes. The complex-
ity of interactions in protein tertiary structures and the
sensitivity of enzymatic activity towards sequence alterations
render enzyme stabilization very challenging. A minimally
invasive strategy involves the use of covalent protein modi-
fications (e.g., PEGylation or glycosylation) being mainly
applied to increase biostability for therapeutic applications.[2]
Alternatively, enzyme stabilization can be achieved by
sequence variation through directed evolution, consensus-
based mutagenesis, or computational approaches,[3] which can
be complemented by the introduction of non-proteinogenic
amino acids.[4] These approaches aim for improved protein
core interactions, structure rigidification, and/or surface
charge redistribution, and often require multiple rounds of
optimization to achieve relevant stabilization.
The stabilization of enzymes has also been achieved by
the introduction of intramolecular crosslinks. Early examples
involve the installation of additional disulfide bridges,[5] which
was later complemented by disulfide mimics that are insensi-
tive to reducing environments.[6] Stabilization by disulfides is
challenging, in particular when replacing residues in the
protein core, as this can cause the loss of non-covalent
interactions, thereby reducing the benefit of crosslinking.[7]
For that reason, the incorporation of disulfides into flexible
protein regions and on the protein surface proved more
successful. However, the short distance of the disulfide bridge
limits its applicability.[8] Alternatively, the crosslinking of
protein termini through lactam formation was applied,[9]
requiring a suitable spatial alignment of the N- and
C-termini. To reduce these structural prerequisites, the
incorporation of non-natural amino acids was pursued to
enable crosslinking with an appropriately aligned cysteine
side chain.[10] However, the necessity of amber stop codon
suppression for the introduction of these non-natural amino
acids complicates protein expression. In addition, the screen-
ing of linker libraries is hampered as the incorporation of such
modified amino acids requires the evolution of a correspond-
ing tRNA synthetase.[11] Taken together, enzyme stabilization
endeavors would greatly benefit from an approach that
enables the installation of modular crosslinks into proteins
only consisting of natural amino acids.
Herein, we report a structure-based stabilization strategy
involving the in situ cyclization of proteins (INCYPRO)
composed entirely of proteinogenic amino acids (Figure 1a).
Using an initial set of monocyclic enzyme variants, we
evaluated the feasibility of crosslinking two intradomain
cysteine residues using a biselectrophile. Subsequently, a tri-
selectrophilic crosslinker was employed to generate a bicyclic
enzyme with high tolerance towards thermal and chemical
stress.
Abstract: Increased tolerance of enzymes towards thermal and
chemical stress is required for many applications and can be
achieved by macrocyclization of the enzyme resulting in the
stabilizing of its tertiary structure. Thus far, macrocyclization
approaches utilize a very limited structural diversity, which
complicates the design process. Herein, we report an approach
that enables cyclization through the installation of modular
crosslinks into native proteins composed entirely of proteino-
genic amino acids. Our stabilization procedure involves the
introduction of three surface-exposed cysteine residues, which
are reacted with a triselectrophile, resulting in the in situ
cyclization of the protein (INCYPRO). A bicyclic version of
sortase A was designed that exhibits increased tolerance
towards thermal as well as chemical denaturation, and
proved to be efficient in protein labeling under denaturing
conditions. In addition, we applied INCYPRO to the KIX
domain, resulting in up to 24 8C increased thermal stability.
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Figure 1. a) Macrocyclization strategy towards stabilized protein terti-
ary structures using a modular bis- or triselectrophilic crosslink.
b) Electrophiles (maleimide 1, 2-bromoacetamide 2, 2-chloroacetamide
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We chose Staphylococcus aureus sortase A (SrtA, aa 60–
206) as the target of our stabilization efforts. SrtA is a trans-
peptidase and an important biomolecular tool enabling the
specific labeling of proteins.[12] The labeling efficiency drops
when higher temperatures or denaturants are used, limiting
its applicability. To stabilize SrtA, we considered a crosslink-
ing strategy that has previously been applied to constrain
peptides and involves the use of biselectrophiles that target
pairs of cysteines.[13] Different from these examples, SrtA
already contains a cysteine (C184) that is crucial for catalytic
activity and may undergo undesired reactions with the
electrophile. For that reason, we first tested four electrophiles
(1–4 ; Figure 1b), previously used for cysteine labeling,
regarding their propensity to react with cysteine C184.
Reaction conditions suitable for preparative-scale protein
modification led to substantial modification of C184 when the
enzyme was incubated with maleimide (1) and 2-bromoace-
tamide (2), but not for 2-chloroacetamide (3) and acrylamide
(4 ; see the Supporting Information, Figure S1 and Table S1).
These differences in the labeling potential are in line with the
electrophilicities of these compounds (1> 2> 3 4).[14] Note-
worthy, C184 is shielded by active-site residues, which reduces
its general accessibility.[15] As thiols tend to undergo rever-
sible addition to acrylamides, we finally chose 2-chloroaceta-
mide (3) as the electrophile for our crosslinkers, which should
enable selective labeling of introduced, solvent-exposed
cysteines. A set of biselectrophilic linkers with 8–17 bridging
atoms (b1–b6 ; Figure 2a) spanning a broad range of distances
(up to 21 , Figure S2) was designed.
Suitable positions for the introduction of cysteine pairs in
SrtA were selected to evaluate their suitability for tertiary-
structure stabilization. We considered surface residues not
involved in substrate recognition and selected pairs that are
located in two different secondary structure elements while
still being in spatial proximity (distance < 20 , based on
NMR structure, PDB ID 1ija). Based on these criteria, six
SrtA variants (S1–S6 ; Figures 2b and S3) were designed,
expressed in E. coli, and purified. Subsequently, crosslinking
reactions with all biselectrophiles were performed, which
showed various degrees of conversion. Formation of the
cyclization product was confirmed by MS and SDS-PAGE
analysis (Figures S4 and S5). While we observed high
conversions for S1, S3, S4, and S6 with all crosslinkers, S2
and S5 showed overall high heterogeneity (Figure S4). After
the reaction, protein samples were dialyzed to remove
unreacted biselectrophiles. Initially, the apparent melting
temperatures (Tm) of all unmodified and crosslinked variants
(as obtained after dialysis) were determined by changes in
tryptophan fluorescence (Figures 2c and S6). Compared to
SrtA (Tm = 59.4 8C), all non-crosslinked variants showed
a lower thermal stability except for S3 (DTm =+ 2.9 8C).
Enzyme crosslinking results in strong stabilization of the
cyclic S3 versions (DTm+ 10.1 8C) while more moderate
effects were observed for the remaining variants. The most
stable versions per variant are S1-b1 (DTm =+ 2.8 8C), S2-b2
(DTm =+ 0.4 8C), S4-b3 (DTm =+ 4.4 8C), S5-b5 (DTm =
+ 3.4 8C), and S6-b1 (DTm =+ 3.9 8C).
SrtA is a transpeptidase that cleaves its peptide recog-
nition motif (LPXTG, Figure 2d) to form a thioester inter-
mediate. This intermediate is preferably attacked by the
N-terminus of oligoglycine to form a new peptide bond
(Figure 2d). In the absence of a suitable nucleophile, water
will attack and hydrolyze the thioester (Figure 2d). To
investigate enzymatic activity, a previously reported probe
system was applied in which a fluorophore/quencher pair is
separated upon SrtA processing (Figure S7). For activity
Figure 2. a) Biselectrophiles (b1–b6) used for the generation of monocyclic enzymes. b) NMR structure of SrtA (PDB: 1ija) with positions of
cysteine variations highlighted. Cysteine pairs (same color) and their positions are shown (for details see Figure S3). c) Heat map representation
of apparent Tm values (heating rate: 1 8C min
1) for linear and crosslinked SrtA variants (75 mm ; for melting curves and apparent Tm values, see
Figure S6). d) Mechanism of the SrtA-mediated transpeptidation reaction (recognition motif: LPXTG). e) Heat map representation of enzymatic
activity (vr, relative to wild-type SrtA) of linear and crosslinked SrtA variants at 65 8C (10 mm enzyme, 10 mm fluorescent probe; for vr values, see
Table S2). Buffer for 2c and 2e : 20 mm HEPES, pH 7.5, 150 mm NaCl, 5 mm CaCl2, 2 mm TCEP; for 3e : including 0.01% Tween 20.
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screening, we chose the hydrolysis reaction[16] at 65 8C, where
wild-type SrtA shows strongly reduced performance (4%
residual activity; Figure S7). Relative to SrtA (vr = 1; Fig-
ure 2e), a number of crosslinked enzymes show increased
activity. Surprisingly, the thermostable cyclic versions of S3
provide reduced enzymatic activity (Figure 2e). In contrast,
crosslinked versions of S4 and S5 exhibit robust activity
enhancements (> twofold; light and dark red, Figure 2e). The
overall highest increase in activity was observed for S4-b3,
which is 3.4-fold more active than SrtA. Taken together, the
observed improvements in the activity at 65 8C are moderate,
indicating that monocyclization may not be sufficient to
convey enough stabilization of the tertiary structure.
To achieve stronger stabilization effects, we aimed for
bicyclization of the enzyme. Notably, the two best performing
SrtA variants S4 and S5 (light and dark blue, Figure 2b) share
one variation site (aa 149). Thus we decided to introduce their
three cysteine variations simultaneously (aa 111, 149, and
177), resulting in variant S7 (Figure 3a), which can form
a bicyclic protein upon reaction with a triselectrophile. In
analogy to bicyclic peptides[17] and mini-proteins,[18] we
selected a C3-symmetric core for our crosslinker, which was
modified with three 2-chloroacetamide groups (t1; Fig-
ure 3b). Triselectrophile t1 involves 13 bridging atoms,
thereby lying between the preferred crosslink ranges of S4
(b3/b4 : 10/11 atoms) and S5 (b5/b6 : 14/17 atoms). The cross-
linking reaction of S7 and t1 proceeds efficiently and provides
stapled enzyme S7-t1 (Figure 3 b). Analytical HPLC-MS
analysis indicates quantitative conversion of S7, clearly
showing the formation of a product with the expected
molecular weight (Figure S8). High-resolution MS analysis
of tryptic fragments confirms the modification of the three
introduced cysteines, also verifying the unmodified state of
C184 (Figure S9, S10, and S11). Importantly, S7-t1 exhibits
strongly increased thermal stability (Tm = 70.6 8C; Figure 3c),
which is considerably higher than that of SrtA (DTm =
+ 11.2 8C) and of the most active monocyclic protein S4-b3
(DTm =+ 6.8 8C). Next, we determined the enzymatic activity
of S7-t1 at 65 8C (Figure 3d). In line with its superior thermal
stability, we observed strongly increased enzymatic activity at
65 8C when compared to SrtA (8.7-fold) and S4-b3 (2.6-fold;
Figure 3d).
Thus far, we had evaluated enzyme activity under hydro-
lytic conditions. Envisioning the application of S7-t1 for
protein labeling, we next investigated transpeptidation at
65 8C with the above described fluorescent probe but now in
the presence of the nucleophile triglycine (transfer; Fig-
ure 2d). Using HPLC-MS as the readout (Figure 4a), we
again observed only very low substrate conversion with SrtA
(dark gray), similar to a treatment without any enzyme (light
gray). In the presence of S7-t1 (red; Figure 4a), the signal of
the starting material (*) was greatly diminished, and two new
peaks appeared. Based on the MS (Figure S12), one peak was
assigned to the C- (~) and the other one to the N-terminal
fragment (&), which appears to be ligated to triglycine.
Importantly, a signal for the hydrolysis product (Dabcyl-
QALPET) was not detected, verifying the correct function-
ality of S7-t1. To assess if protein unfolding at elevated
temperature is reversible, we compared the enzymatic activity
of SrtA and S7-t1 at 37 8C before and after heating (85 8C,
Figure S13). Notably, the transpeptidase activity of both
enzymes is not affected by the heating/cooling cycle, indicat-
ing reversible unfolding.
Next, we determined the thermal activity profile of the
transpeptidation reaction (Figure 4 b). Between 37 8C and
55 8C, the activity of SrtA (gray) and S7-t1 (red) is similar,
exhibiting only low temperature dependence. Above 55 8C,
both enzymes experience a loss in activity, which is very
severe for SrtA, resulting in almost complete inactivation at
65 8C (Figure 4 b). For S7-t1, the activity reduction is much
smaller, with residual activities of 63 % (at 65 8C) and 27 % (at
70 8C) relative to 37 8C. Compared to SrtA, S7-t1 shows an
approximately 10 8C increased tolerance towards thermal
stress, which correlates well with its + 11.2 8C higher apparent
melting temperature. Enhanced thermal stability often goes
in hand with a resistance towards denaturants such as
guanidinium hydrochloride (GdnHCl). For that reason, the
impact of GdnHCl on the transpeptidase activity was inves-
tigated (Figure 4 c), revealing that the activities of SrtA and
S7-t1 hardly depend on the denaturant concentrations up to
0.5m. Between 0.75 and 1.5m, S7-t1 is significantly more
active than SrtA. Most notably, at 1m GdnHCl, SrtA does not
yield any product (vr< 1%; Figure 4c) while S7-t1 still
provides 40 % residual activity (compared to the absence of
Figure 3. a) NMR structure of SrtA (PDB: 1ija) with positions of
cysteine variations in S7 highlighted. b) Chemical structure of triselec-
trophile t1 and Coomassie-stained SDS-PAGE gel showing protein
bands after incubation with t1 (50 mm S7, 1 mm t1, 50 mm HEPES,
pH 8.5, 150 mm NaCl, 5 mm CaCl2, 2 mm TCEP). c) Melting curves of
SrtA, S4-b3, and S7-t1 including apparent Tm values (heating rate
1 8C min1). d) Fluorescence readout of enzymatic activity at 65 8C
(10 mm enzyme, 10 mm fluorescent probe). Buffer for 3c and 3d :
20 mm HEPES, pH 7.5, 150 mm NaCl, 5 mm CaCl2, 2 mm TCEP, with
0.01% Tween 20 for (d).
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GdnHCl). At higher GdnHCl concentrations ( 2m), both
enzymes are inactive.
Thus far, we had applied S7-t1 for the labeling of a short
test peptide. Next, we were interested whether S7-t1 would
also be useful for protein labeling in particular under
conditions where wild-type SrtA does not provide sufficient
activity. For that purpose, we chose a-synuclein (a-Syn) as the
target. a-Syn comprises 140 amino acids and can form
pathogenic fibrils, which are associated with the onset of
various neurodegenerative diseases including Parkinsons
disease.[19] a-Syn fibrils can be solubilized using GdnHCl.[20]
We designed an a-Syn version with a C-terminal SrtA
recognition motif (Figure S14) to allow for labeling. Follow-
ing expression and purification, soluble a-Syn (A) was
subjected to fibril formation and ultracentrifugation.[20]
Insoluble fibrils were washed and treated with buffer either
lacking (B) or containing (C) GdnHCl (1m).[20] When
comparing the resulting soluble fractions (B and C) with the
purified and soluble form of a-Syn (A; Figure 4d), we
observed resolubilization only in the presence (C) but not in
the of absence (B) of GdnHCl. To investigate protein
labeling, these soluble samples (A, B, C) were incubated
with either SrtA or S7-t1 and a fluorescent substrate (Fig-
ure S14). We then performed analysis by SDS-PAGE employ-
ing a fluorescence imager for readout. For soluble a-Syn prior
to fibril formation (A), and therefore in the absence of
GdnHCl, SrtA and S7-t1 gave rise to intense bands, indicating
efficient protein labeling (Figures 4e and S15). As expected,
under resolubilization conditions lacking GdnHCl (B) and
therefore also lacking soluble a-Syn, we did not observe any
fluorescence signal (B; Figure 4e and S15). On the contrary,
for resolubilization with GdnHCl (1m), a-Syn labeling occurs
but only with S7-t1 and not with wild-type SrtA (C). Notably,
differences in the fluorescence band intensities for S7-t1 (A
vs. C; Figure 4e and S15) correlate well with the amount of a-
Syn in the soluble fractions (A vs. C; Figure 4d), indicating
good labeling efficiencies for S7-t1 in the presence of
GdnHCl.
To assess the broader applicability of protein stabilization
by bicyclization, we chose the KIX domain from the human
CREB binding protein as a second example (Figure 5a). KIX
is an adaptor domain with multiple protein binding partners,
such as mixed-lineage leukemia (MLL), and is composed of
a central three a-helix bundle (a1, a2, a3). The junction
between this bundle and the C-terminal 310 helix (G1) is
crucial for structural integrity (Figure 5a).[21] Thus we focused
on this area for tertiary-structure stabilization searching for
three positions suitable for cysteine incorporation. Based on
our experience with SrtA stabilization, the following guide-
lines were applied: 1) Solvent-accessible residues were con-
sidered that are 2) located in three distinct secondary
structures while 3) facing the same side of the protein and
4) spanning a triangle with side lengths between 6 and 17 
(Ca-Ca distance). Based on these criteria, we selected H594,
Figure 4. a) HPLC chromatograms (440 nm) of the transpeptidation
reaction (12 h at 65 8C) with a fluorescent probe (*) in the absence of
enzyme (light gray), with SrtA (dark gray), or with S7-t1 (red). Product
formation (~, &) was only observed in the presence of S7-t1 (50 mm
enzyme, 10 mm probe, 2.5 mm GGG; for MS spectra of signals, see
Figure S12). b) Temperature dependence of the enzymatic activity (vr,
relative to SrtA at 37 8C; 10 mm enzyme, 10 mm probe, 2.5 mm GGG,
buffer: 20 mm HEPES, pH 7.5, 150 mm NaCl, 5 mm CaCl2, 2 mm
TCEP, 0.01% Tween 20). Values are mean of triplicate (+ / 1s, *
p<0.05, ** p<0.01, *** p<0.001, ns: not significant). c) Relative
enzymatic activity (vr, relative to SrtA in the absence of GdnHCl) at
37 8C for various concentrations of GdnHCl (for details see the
Methods Section in the Supporting Information). d) Coomassie-
stained SDS-PAGE gel showing the soluble a-Syn fractions before fibril
formation (A) and after resolubilization in the absence (B) and
presence (C) of GdnHCl (1 m). e) Fluorescence readout (lem = 520 nm)
of a-Syn labeling using soluble fractions before fibril formation A
(without GdnHCl) and after re-solubilization B (without GdnHCl) and
C (1 m GdnHCl) with either SrtA or S7-t1 (for details see Figures S14
and S15).
Figure 5. a) NMR structure of KIX (PDB: 2agh), with positions of
cysteine variations in K1 highlighted. The secondary structural ele-
ments have been named. b) Melting curves of KIX, K1-t1, and K1-t2,
including apparent Tm values.
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L599, and R646 for cysteine introduction, resulting in KIX
variant K1 (Figures 5a and S16).
For crosslinking, we chose triselectrophile t1 (n = 2,
Figure 3b) and a shorter version t2 (n = 1) as we noticed
that the distances between the three variation sites in K1 (7.8,
10.0, and 11.5 ; Figure S16) are shorter than those in S7 (8.5,
12.4, and 15.7 ; Figure S8). The crosslinking with both
triselectrophiles proceeds efficiently as confirmed by SDS-
PAGE (Figure S17) and HPLC-MS analysis (Figure S18). To
evaluate if crosslinking affects the tertiary structure, we
compared the affinity of KIX and both bicyclic variants (K1-
t1 and K1-t2) to its binding partner MLL (for the sequence
see Figure S19). Using a fluorescence polarization assay,
similar binding affinities were observed for KIX, K1-t1, and
K1-t2 (Kd = 0.6, 0.9, and 0.9 mm, respectively; Figure S19).
Then, we determined apparent melting temperatures (Fig-
ure 5b) to find a strongly increased thermal stability for K1-t1
and K1-t2 (DTm =+ 20.6 8C and + 24.6 8C, respectively) when
compared to KIX. Notably, both triselectrophiles have
a similar stabilizing effect, with the shorter crosslink t2
performing best. Based on these results, we were also
interested in evaluating the effect of triselectrophile t2 on
SrtA variant S7. Again, the crosslinking reaction proceeds
efficiently, resulting in bicyclic enzyme S7-t2 (Figure S20).
Notably, we observe a similar thermal stabilization for S7-t2
(DTm =+ 11.5 8C, Figure S20) as for S7-t1 (DTm =+ 11.2 8C),
indicating tolerance towards minor variations in the length of
the crosslink.
In summary, we have reported an approach for the in situ
cyclization of proteins (INCYPRO) enabling a structure-
based stabilization of recombinant proteins that are entirely
composed of proteinogenic amino acids. The use of synthetic
electrophiles for protein cyclization gives straightforward
access to diverse crosslinked architectures with tunable length
and flexibility. We applied INCYPRO to generate the bicyclic
SrtA variant S7-t1, which exhibited strongly increased toler-
ance towards thermal and chemical denaturation. Impor-
tantly, S7-t1 proved efficient in labeling a-Syn in the presence
of 1m GdnHCl. Under these conditions, wild-type SrtA did
not show enzymatic activity. From our findings with SrtA, we
derived guidelines for the bicyclization and stabilization of
proteins and applied them to the KIX domain. A three-
cysteine KIX variant was designed and reacted with two
different C3-symmetric triselectrophiles to provide bicyclic
KIX versions with up to 24 8C increased thermal stability. In
the future, we envision the use of crosslinking agents that
allow the introduction of an additional functionality such as
an affinity handle (e.g., for enzyme purification/recycling[22] or
proximity-assisted enzyme activity[23]). Taken together, the
presented protein stabilization technology holds the potential
to give rapid access to novel stabilized enzymes, providing an
opportunity for the simultaneous incorporation of additional
functions.
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